Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

Inclusion Criteria:

• Participants to provide a signed informed consent at the time of enrollment perprotocol,

• Male or female aged 18 or over at initiation of belimumab,

• Participants received belimumab for the treatment of active LN prescribed as perlocal label in combination with standard immunosuppressive therapy/ies at initiationof belimumab,

• Participants initiated belimumab 6 to 24 months prior to study enrollment,

• Accessibility of medical records starting at belimumab initiation (includingaccessibility of medical records for the prior 12 months and confirmatory biopsywithin the prior 24 months from belimumab initiation),

• Biopsy-confirmed diagnosis of active LN in the two-years prior to the initiation ofbelimumab

• Class III (focal LN) with or without Class V (membranous LN),

• Class IV (diffuse LN) with or without Class V,

• Class V.

Exclusion Criteria:

• Participants receiving renal replacement therapy at initiation of belimumab,

• Participant is concomitantly receiving another biologic at initiation of belimumab,

• Participants in a clinical trial during the observation period (with the exceptionof allowing participation in other non-interventional studies),

• Participant is pregnant at the initiation of belimumab,

• Participant with a kidney transplant at the initiation of belimumab,

• Participants will be excluded from the study if they are planning to become pregnantor are pregnant at study enrollment.